[New valuation musings; reorganized with new section on FoB’s; new info on source of Lovenox sales by indication.]
What is MNTA’s business all about? #msg-25513125 Quick primer by ThomasS #msg-28919271Morgan Stanley webcast: a “must-listen” (4/30/08) #msg-28748329MNTA helps FDA diagnose contaminated heparin #msg-269003962008 news flow #msg-25473104 Capsule explanation of proprietary technology #msg-19626947 Sugars, peptides and glycoproteins, in that order #msg-24624700 Apropos to above (2005 PR) #msg-25473420 Characterizing a compound by “ruling out” structures (1) #msg-28865474 Characterizing a compound by “ruling out” structures (2) #msg-26876819 4Q07 CC transcript (2/14/08) #msg-26808908 Summary of BioCEO webcast (2/13/08)
Generic-Lovenox program #msg-28896384MNTA to resubmit ANDA in 3Q08 #msg-122223052006 partnership with Sandoz #msg-25534402 Economics of the Lovenox partnership #msg-28903176Lovenox sells $4.5B per year #msg-28934793 Sole generic Lovenox->largest-selling generic of all time #msg-28936334 Where do Lovenox sales come from? #msg-26739674 Lovenox has 53% of US heparin market by volume #msg-28900092 Sole vs multiple approvals: how will we know? #msg-25933221 FDA issues non-approvable letter (11/5/07) #msg-24636279 Competing Lovenox ANDA’s non-approvable at this time #msg-26882378 Status of SNY’s Lovenox patent #msg-24627410 Musings on timing of EU submission (Dew) #msg-28838788 Existing and future anticoagulants
Generic-Copaxone program #msg-12222305 Copaxone (M356) is part of 2006 NVS collaboration #msg-28903357Copaxone sales keep growing #msg-27177236 Copaxone has 25% worldwide share of MS market #msg-26893858 Musings on the attractiveness of Copaxone program #msg-24627410 Speculation on the timeline #msg-28375793 Copaxone in the ifn-refractory setting #msg-28555109 Latest data from AAN (1) #msg-28589156 Latest data from AAN (2)
Follow-on Biologics (FoB) programs #msg-27114485US FoB’s are a question of when not if #msg-26837144Salient FoB quote from MNTA’s CEO #msg-122223052006 FoB partnership with Sandoz #msg-25514154 Speculation on the FoB’s to be developed (ThomasS)
Competition #msg-28838788 Existing and future anticoagulants
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.